JUNS.US Jupiter Neurosciences, Inc. Common Stock

Healthcare Pharmaceuticals USA Stocks
1.76 USD
Close of Nov 15, 2026
1.76 101.25
Market cap
USD 2.32M
P/E
-
P/B
44.71x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is JUNS.US undervalued?

Graham number

The Graham number of Jupiter Neurosciences, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Jupiter Neurosciences, Inc. Common Stock fundamental analysis

No fundamental analysis for Jupiter Neurosciences, Inc. Common Stock yet.

Jupiter Neurosciences, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Jupiter Neurosciences, Inc. Common Stock

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease; JNS108, which is in Phase II …

Full company profile